Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Peficitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 known ✓ | P52333 | 18/20 | 1.00 |
| ▸ | JAK2 known ✓ | O60674 | 17/20 | 1.00 |
| ▸ | JAK1 known ✓ | P23458 | 16/20 | 1.00 |
| ▸ | TYK2 known ✓ | P29597 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Peficitinib SCHEMBL16199899 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL9990240 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL16199902 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL1154418 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL17645135 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL24212690 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL9990248 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL1154421 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL22404910 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 | |
| Peficitinib SCHEMBL4447032 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119552157-A | Picetirizine preparation method of nylon | 齐鲁制药有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-118717746-A | Pharmaceutical composition with JAK inhibiting effect | 辽宁新中现代医药有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-117838689-A | Application of pefitinib in preparation of medicine for treating influenza virus infection | 暨南大学 | 2024-04-09 | — | — | CN | disclosed |
| US-20230192711-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192711-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| CN-115651890-A | Method for transdifferentiation of fibroblasts into papilla-like cells and application of method | 北京雍禾医疗投资管理有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220168316-A1 | METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS | CAMP4 THERAPEUTICS CORPORATION | 2022-06-02 | — | — | US | disclosed |
| US-20220168418-A1 | PREVENTION OR MITIGATION OF T-CELL ENGAGING AGENT-RELATED ADVERSE EFFECTS | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220073524-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2022-03-10 | — | — | US | disclosed |
| EP-1966200-B1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC (JP) | 2014-10-29 | — | — | EP | disclosed |
| CN-101351466-B | Heterocyclic Janus kinase 3 inhibitors | ASTELLAS PHARMA INC | 2011-08-10 | — | — | CN | disclosed |
| US-20110039822-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2011-02-17 | — | — | US | disclosed |
| US-7879844-B2 | useful for treating or preventing diseases caused by undesirable cytokine signal transmission such as autoimmune diseases, inflammatory diseases, allergies, transplant rejection, multiple sclerosis, arthritis, psoriasis, asthma, dermatitis, Alzheimer's disease, atherosclerosis, cancer and leukemia | ASTELLAS PHARMA INC. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20090270376-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270376-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270376-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| CN-101351466-A | Heterocyclic Janus kinase 3 inhibitors | ASTELLAS PHARMA INC (JP) | 2009-01-21 | — | — | CN | disclosed |
| EP-1966200-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | Astellas Pharma Inc. (JP) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007077949-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | JAK3 3/4885JAK2 2/4885JAK1 1/4885 |
| US-20220168418-A1 | PREVENTION OR MITIGATION OF T-CELL ENGAGING AGENT-RELATED ADVERSE EFFECTS | ICOS, IL2, NFATC1 | JAK3 26/4885JAK2 24/4885JAK1 11/4885 |
| US-20230192711-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | JAK2, JAK1, JAK3 | JAK3 3/4885JAK2 1/4885JAK1 2/4885 |
| US-20110039822-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
| US-20090270376-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK1, IRAK3 | JAK3 1/4885JAK2 4/4885JAK1 2/4885 |
| US-20220073524-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | JAK2, JAK1, JAK3 | JAK3 3/4885JAK2 1/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.